Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 32, 56-60

Access to New Medications for the Treatment of Drug-Resistant Tuberculosis: Patient, Provider and Community Perspectives

Affiliations
Review

Access to New Medications for the Treatment of Drug-Resistant Tuberculosis: Patient, Provider and Community Perspectives

Erica Lessem et al. Int J Infect Dis.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is on the rise, and is difficult to treat. The approval of two new drugs, bedaquiline and delamanid, and growing evidence for the use of linezolid, offer renewed hope for addressing MDR-TB. However, access to these medicines remains a significant challenge. These drugs have not been registered for TB in most settings; barriers to preapproval access persist; and high pricing and intellectual property restrictions limit access. Many unanswered research questions about optimal use of these drugs also limit access, particularly for vulnerable populations. This review outlines challenges in accessing drugs encountered from the perspective of clinicians, patients and affected communities, and offers potential solutions.

Keywords: Access; Community; Compassionate use; Drugs; Multidrug-resistant tuberculosis; Tuberculosis.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback